Biologic Nanoparticles and Platelet Reactivity

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2009 Oct 21

PMID 19839809

Citations 12

Authors

Virginia M Miller

Larry W Hunter

Kevin Chu

Vivasvat Kaul

Phillip D Squillace

John C Lieske

Muthuvel Jayachandran

Affiliations

Soon will be listed here.

Abstract

Aim: Nanosized particles (NPs) enriched in hydroxyapatite and protein isolated from calcified human tissue accelerate occlusion of endothelium-denuded arteries when injected intravenously into rabbits. Since platelet aggregation and secretory processes participate in normal hemostasis, thrombosis and vascular remodeling, experiments were designed to determine if these biologic NPs alter specific platelet functions in vitro.

Methods: Platelet-rich plasma was prepared from citrate anticoagulated human blood. Platelet aggregation and ATP secretion were monitored in response to thrombin receptor agonists peptide (10 microM) or convulxin (50 microg/ml) prior to and following 15 min incubation with either control solution, human-derived NPs, bovine-derived NPs or crystals of hydroxyapatite at concentrations of 50 and 150 nephelometric turbidity units.

Results: Incubation of platelets for 15 min with either human- or bovine-derived NPs reduced aggregation induced by thrombin receptor activator peptide and convulxin in a concentration-dependent manner. Hydroxyapatite caused a greater inhibition than either of the biologically derived NPs. Human-derived NPs increased ATP secretion by unstimulated platelets during the 15 min incubation period.

Conclusion: Effects of bovine-derived and hydroxyapatite NPs on basal release of ATP were both time and concentration dependent. These results suggest that biologic NPs modulate both platelet aggregation and secretion. Biologically derived NPs could modify platelet responses within the vasculature, thereby reducing blood coagulability and the vascular response to injury.

Citing Articles

Facilitated and Controlled Strontium Ranelate Delivery Using GCS-HA Nanocarriers Embedded into PEGDA Coupled with Decortication Driven Spinal Regeneration.

Chiang C, Chen C, Manga Y, Huang S, Chao K, Jheng P Int J Nanomedicine. 2021; 16:4209-4224.

PMID: 34188470 PMC: 8235953. DOI: 10.2147/IJN.S274461.

Carbon Dot Nanoparticles Exert Inhibitory Effects on Human Platelets and Reduce Mortality in Mice with Acute Pulmonary Thromboembolism.

Lee T, Jayakumar T, Thanasekaran P, Lin K, Chen H, Veerakumar P Nanomaterials (Basel). 2020; 10(7).

PMID: 32605190 PMC: 7407909. DOI: 10.3390/nano10071254.

Effect of Size and Concentration of PLGA-PEG Nanoparticles on Activation and Aggregation of Washed Human Platelets.

Bakhaidar R, Green J, Alfahad K, Samanani S, Moollan N, ONeill S Pharmaceutics. 2019; 11(10).

PMID: 31590303 PMC: 6835715. DOI: 10.3390/pharmaceutics11100514.

Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior.

Santos C, Turiel S, Gomes P, Costa E, Santos-Silva A, Quadros P J Nanobiotechnology. 2018; 16(1):27.

PMID: 29566760 PMC: 5863823. DOI: 10.1186/s12951-018-0357-y.

Hydroxyapatite as a Vehicle for the Selective Effect of Superparamagnetic Iron Oxide Nanoparticles against Human Glioblastoma Cells.

Pernal S, Wu V, Uskokovic V ACS Appl Mater Interfaces. 2017; 9(45):39283-39302.

PMID: 29058880 PMC: 5796653. DOI: 10.1021/acsami.7b15116.

References

Brown D, Stone V, Findlay P, MacNee W, Donaldson K . Increased inflammation and intracellular calcium caused by ultrafine carbon black is independent of transition metals or other soluble components. Occup Environ Med. 2000; 57(10):685-91. PMC: 1739870. DOI: 10.1136/oem.57.10.685. View

Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik D, Aikawa E . Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2007; 117(3):379-87. PMC: 2663426. DOI: 10.1161/CIRCULATIONAHA.107.741181. View

Hjelle J, Poxton I, Kajander E, Ciftcioglu N, Jones M, Caughey R . Endotoxin and nanobacteria in polycystic kidney disease. Kidney Int. 2000; 57(6):2360-74. DOI: 10.1046/j.1523-1755.2000.00096.x. View

Koziara J, Oh J, Akers W, Ferraris S, Mumper R . Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm Res. 2005; 22(11):1821-8. DOI: 10.1007/s11095-005-7547-7. View

Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R, Frohlich E . The role of nanoparticle size in hemocompatibility. Toxicology. 2009; 258(2-3):139-47. DOI: 10.1016/j.tox.2009.01.015. View

Jayachandran M, Litwiller R, Owen W, Heit J, Behrenbeck T, Mulvagh S . Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008; 295(3):H931-H938. PMC: 2544500. DOI: 10.1152/ajpheart.00193.2008. View

Schoppet M, Shroff R, Hofbauer L, Shanahan C . Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. Kidney Int. 2007; 73(4):384-90. DOI: 10.1038/sj.ki.5002696. View

Piccin A, Murphy W, Smith O . Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2006; 21(3):157-71. DOI: 10.1016/j.blre.2006.09.001. View

Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet J . Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999; 93(10):3451-6. View

10.

Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T . Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005; 146(6):882-93. PMC: 1751219. DOI: 10.1038/sj.bjp.0706386. View

11.

Young J, Martel J, Young L, Wu C, Young A, Young D . Putative nanobacteria represent physiological remnants and culture by-products of normal calcium homeostasis. PLoS One. 2009; 4(2):e4417. PMC: 2636888. DOI: 10.1371/journal.pone.0004417. View

12.

Schwartz M, Lieske J, Kumar V, Farell-Baril G, Miller V . Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: proof of principle. Int J Nanomedicine. 2008; 3(2):243-8. PMC: 2527666. DOI: 10.2147/ijn.s2473. View

13.

Kumar V, Farell G, Yu S, Harrington S, Fitzpatrick L, Rzewuska E . Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J Investig Med. 2006; 54(7):412-24. DOI: 10.2310/6650.2006.06021. View

14.

Donaldson K, Stone V . Current hypotheses on the mechanisms of toxicity of ultrafine particles. Ann Ist Super Sanita. 2004; 39(3):405-10. View

15.

Miyamoto M, SASAKAWA S, Ozawa T, Kawaguchi H, Ohtsuka Y . Platelet aggregation induced by latex particles. I. Effects of size, surface potential and hydrophobicity of particles. Biomaterials. 1989; 10(4):251-7. DOI: 10.1016/0142-9612(89)90101-4. View

16.

Jelic T, Malas A, Groves S, Jin B, Mellen P, Osborne G . Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med J. 2004; 97(2):194-8. DOI: 10.1097/01.SMJ.0000077067.44311.F0. View

17.

Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I . Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008; 100(4):663-9. View

18.

Ross R . Cell biology of atherosclerosis. Annu Rev Physiol. 1995; 57:791-804. DOI: 10.1146/annurev.ph.57.030195.004043. View

19.

Amabile N, Guerin A, Leroyer A, Mallat Z, Nguyen C, Boddaert J . Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol. 2005; 16(11):3381-8. DOI: 10.1681/ASN.2005050535. View

20.

Martel J, Young J . Purported nanobacteria in human blood as calcium carbonate nanoparticles. Proc Natl Acad Sci U S A. 2008; 105(14):5549-54. PMC: 2291092. DOI: 10.1073/pnas.0711744105. View